{
    "nct_id": "NCT03733210",
    "official_title": "Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer",
    "inclusion_criteria": "* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.\n* Subjects diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Subjects with recurrent disease or a new primary will be allowed.\n* Planned standard of care surgery with curative intent for squamous cell carcinoma.\n* Hemoglobin ≥ 9 gm/dL.\n* White blood cell count > 3000/mm³.\n* Platelet count ≥ 100,000/mm³.\n* Serum creatinine ≤ 1.5 times upper reference range.\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.\n* Previous bilateral neck dissection.\n* History of infusion reactions to monoclonal antibody therapies.\n* Pregnant or breastfeeding.\n* Magnesium or potassium lower than the normal institutional values.\n* Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.\n* Severe renal disease or anuria.\n* Known hypersensitivity to deferoxamine or any of its components.",
    "miscellaneous_criteria": ""
}